Generation Bio (GBIO)

• Market cap: $40.1M
• 1 day: 6.44%
• 5 days: -4.49%
• 1 month: -10.26%
• 3 months: 49.5%
• 6 months: 12.26%
• Year to date: -46.4%
• 1 year: -76.1%
• 5 years: -98.01%
• 10 years: -97.59%
• Sector: Healthcare
• Industry: Biotechnology

About: Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Employees: 115

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.94% less ownership

Funds ownership: 7.12% [Q1] → 6.18% (-0.94%) [Q2]

25% less funds holding

Funds holding: 79 [Q1] → 59 (-20) [Q2]

31% less capital invested

Capital invested by funds: $19.3M [Q1] → $13.3M (-$6.03M) [Q2]

56% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 25

59% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 34

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7
• Avg. target: $10.67
• High target: $15

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Canaccord Genuity Whitney Ijem	$10	Buy Maintained	18 Aug 2025
Needham Gil Blum	$15	Buy Reiterated	13 Aug 2025
Wedbush David Nierengarten	$7	Neutral Downgraded	13 Aug 2025